Patents by Inventor Anil Koul

Anil Koul has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PZA and cytochrome Bc1 inhibitor combination treatment
    Patent number: 11918575
    Abstract: The present invention relates to novel combinations, which are useful in the treatment of tuberculosis.
    Type: Grant
    Filed: December 2, 2021
    Date of Patent: March 5, 2024
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Koenraad Jozef Lodewijk Marcel Andries, Anil Koul, Maria Cristina Villellas Arilla
  • Treatment of RSV with combination product
    Patent number: 11369612
    Abstract: The present invention is directed to the combination of the RSV inhibiting Compound A, i.e. 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, and the RSV inhibiting Compound B, i.e. (1S,2S)-2-[4-[7-cyclopropyl-5-[(1R)-1-methyl-3,4-dihydro-1H-isoquinoline-2-carbonyl]pyrazolo[1,5-a]pyrimidin-2-yl]-3-fluoro-phenyl]cyclopropanecarboxylic acid for treating or ameliorating RSV infection. The invention further relates to the combination product of Compound A and Compound B, a pharmaceutical product comprising Compound A and Compound B, the use of the combination of Compound A and Compound B—or the pharmaceutical product comprising Compound A and Compound B—for the treatment of RSV infection, and a method of treating or ameliorating RSV infection in a subject in need thereof comprising administering the combination of Compound A and Compound B in an effective amount to said subject.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: June 28, 2022
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Nina Ysebaert, Nele Isa E. Goeyvaerts, Dirk André Emmy Roymans, Anil Koul
  • COMBINATION THERAPY
    Publication number: 20220088012
    Abstract: The present invention relates to novel combinations, which are useful in the treatment of tuberculosis.
    Type: Application
    Filed: December 2, 2021
    Publication date: March 24, 2022
    Applicant: Janssen Sciences Ireland Unlimited Company
    Inventors: Koenraad Jozef Lodewijk Marcel Andries, Anil Koul, Maria Cristina Villellas Arilla
  • PZA and cytochrome bc1 inhibitor combination treatment
    Patent number: 11224596
    Abstract: The present invention relates to novel combinations, which are useful in the treatment of tuberculosis.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: January 18, 2022
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Koenraad Jozef Lodewijk Marcel Andries, Anil Koul, Maria Cristina Villellas Arilla
  • RSV antiviral pyrazolo- and triazolo-pyrimidine compounds
    Patent number: 11084826
    Abstract: The invention concerns novel substituted pyrazolo- and triazolo-pyrimidine compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: August 10, 2021
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: David Francis Alain Lançois, Jérôme Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Dirk André Emmy Roymans, Boris Rogovoy, Vadim Bichko, Delphine Yvonne Raymonde Lardeau, Antoine Benjamin Michaut, Anil Koul
  • TREATMENT OF RSV WITH COMBINATION PRODUCT
    Publication number: 20210236496
    Abstract: The present invention is directed to the combination of the RSV inhibiting Compound A, i.e. 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, and the RSV inhibiting Compound B, i.e. (1S,2S)-2-[4-[7-cyclopropyl-5-[(1R)-1-methyl-3,4-dihydro-1H-isoquinoline-2-carbonyl]pyrazolo[1,5-a]pyrimidin-2-yl]-3-fluoro-phenyl]cyclopropanecarboxylic acid for treating or ameliorating RSV infection. The invention further relates to the combination product of Compound A and Compound B, a pharmaceutical product comprising Compound A and Compound B, the use of the combination of Compound A and Compound B—or the pharmaceutical product comprising Compound A and Compound B—for the treatment of RSV infection, and a method of treating or ameliorating RSV infection in a subject in need thereof comprising administering the combination of Compound A and Compound B in an effective amount to said subject.
    Type: Application
    Filed: December 4, 2018
    Publication date: August 5, 2021
    Inventors: Nina YSEBAERT, Nele Isa E. GOEYVAERTS, Dirk André Emmy ROYMANS, Anil KOUL
  • RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS
    Publication number: 20200223855
    Abstract: The invention concerns novel substituted pyrazolo- and triazolo-pyrimidine compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.
    Type: Application
    Filed: March 30, 2020
    Publication date: July 16, 2020
    Inventors: David Francis Alain LANÇOIS, Jérôme Émile Georges GUILLEMONT, Pierre Jean-Marie Bernard RABOISSON, Dirk André Emmy ROYMANS, Boris ROGOVOY, Vadim BICHKO, Delphine Yvonne Raymonde LARDEAU, Antoine Benjamin MICHAUT, Anil KOUL
  • RSV antiviral pyrazolo- and triazolo-pyrimidine compounds
    Patent number: 10611769
    Abstract: The invention concerns novel substituted pyrazolo- and triazolo-pyrimidine compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: April 7, 2020
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: David Francis Alain Lançois, Jérôme Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Dirk André Emmy Roymans, Boris Rogovoy, Vadim Bichko, Delphine Yvonne Raymonde Lardeau, Antoine Benjamin Michaut, Anil Koul
  • COMBINATION THERAPY
    Publication number: 20200016154
    Abstract: The present invention relates to novel combinations, which are useful in the treatment of tuberculosis.
    Type: Application
    Filed: February 28, 2018
    Publication date: January 16, 2020
    Applicant: Janssen Sciences Ireland Unlimited Company
    Inventors: Koenraad Jozef Lodewijk Marcel ANDRIES, Anil KOUL, Maria Cristina VILLELLAS ARILLA
  • Antibacterial cyclopenta[C]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones
    Patent number: 10526331
    Abstract: The present invention is related to novel compounds of formula (I) that inhibit the activity of the FabI enzyme which are therefore useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: January 7, 2020
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Jerôme Emile Georges Guillemont, David Francis Alain Lançois, Magali Madeleine Simone Motte, Anil Koul, Wendy Mia Albert Balemans, Eric Pierre Alexandre Arnoult
  • Antibacterial cyclopenta[C]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones
    Patent number: 10501463
    Abstract: The present invention is related to novel compounds of formula (I) that inhibit the activity of the FabI enzyme which are therefore useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: December 10, 2019
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Jerôme Emile Georges Guillemont, David Francis Alain Lançois, Magali Madeleine Simone Motte, Anil Koul, Wendy Mia Albert Balemans, Eric Pierre Alexandre Arnoult
  • RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS
    Publication number: 20190248793
    Abstract: The invention concerns novel substituted pyrazolo- and triazolo-pyrimidine compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.
    Type: Application
    Filed: February 11, 2019
    Publication date: August 15, 2019
    Inventors: David Francis Alain LANÇOIS, Jérôme Émile Georges GUILLEMONT, Pierre Jean-Marie Bernard RABOISSON, Dirk André Emmy ROYMANS, Boris ROGOVOY, Vadim BICHKO, Delphine Yvonne Raymonde LARDEAU, Antoine Benjamin MICHAUT, Anil KOUL
  • Combination products for the treatment of RSV
    Patent number: 10363253
    Abstract: The present invention is directed to the combination of the RSV inhibiting Compound A, i.e. 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl) 1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, and one or more RSV inhibiting Compound B selected from from ribavirin, GS-5806, MDT-637, BTA-9881, BMS-433771, YM-543403, A-60444, TMC-353121, RFI-641, CL-387626, MBX-300, AZ-27, MEDI8897, CR9501, palivizumab, 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-benzimidazol-2-yl}methyl)-1 cyclopropyl-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, 3-[[7-chloro-3-(2 ethyl-sulfonylethyl)imidazo[1,2-a]pyridin-2-yl]methyl]-1-cyclopropyl-imidazo[4,5-c]pyridin-2 one, N-(2-fluoro-6-methylphenyl)-6-(4-(5-methyl-2-(7-oxa-2-azaspiro[3.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: July 30, 2019
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Nina Ysebaert, Nele Isa E. Goeyvaerts, Dirk André E. Roymans, Anil Koul
  • ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES
    Publication number: 20190194194
    Abstract: The present invention is related to novel compounds of formula (I) that inhibit the activity of the FabI enzyme which are therefore useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.
    Type: Application
    Filed: February 26, 2019
    Publication date: June 27, 2019
    Inventors: Jerôme Emile Georges Guillemont, David Francis Alain Lançois, Magali Madeleine Simone Motte, Anil Koul, Wendy Mia Albert Balemans, Eric Pierre Alexandre Arnoult
  • ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES
    Publication number: 20190084982
    Abstract: The present invention is related to novel compounds of formula (I) that inhibit the activity of the FabI enzyme which are therefore useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.
    Type: Application
    Filed: November 16, 2018
    Publication date: March 21, 2019
    Inventors: Jerôme Emile Georges Guillemont, David Francis Alain Lançois, Magali Madeleine Simone Motte, Anil Koul, Wendy Mia Albert Balemans, Eric Pierre Alexandre Arnoult
  • COMBINATION PRODUCTS FOR THE TREATMENT OF RSV
    Publication number: 20190054084
    Abstract: The present invention is directed to the combination of the RSV inhibiting Compound A, i.e. 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl) 1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, and one or more RSV inhibiting Compound B selected from from ribavirin, GS-5806, MDT-637, BTA-9881, BMS-433771, YM-543403, A-60444, TMC-353121, RFI-641, CL-387626, MBX-300, AZ-27, MEDI8897, CR9501, palivizumab, 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-benzimidazol-2-yl}methyl)-1 cyclopropyl-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, 3-[[7-chloro-3-(2 ethyl-sulfonylethyl)imidazo[1,2-a]pyridin-2-yl]methyl]-1-cyclopropyl-imidazo[4,5-c]pyridin-2 one, N-(2-fluoro-6-methylphenyl)-6-(4-(5-methyl-2-(7-oxa-2-azaspiro[3.
    Type: Application
    Filed: February 2, 2017
    Publication date: February 21, 2019
    Inventors: Nina YSEBAERT, Nele Isa E. GOEYVAERTS, Dirk André E. ROYMANS, Anil KOUL
  • RSV antiviral pyrazolo- and triazolo-pyrimidine compounds
    Patent number: 10208048
    Abstract: The invention concerns novel substituted pyrazolo- and triazolo-pyrimidine compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: February 19, 2019
    Assignee: Janssen Sciences Ireland UC
    Inventors: David Francis Alain Lançois, Jérôme Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Dirk André Emmy Roymans, Boris Rogovoy, Vadim Bichko, Delphine Yvonne Raymonde Lardeau, Antoine Benjamin Michaut, Anil Koul
  • Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones
    Patent number: 10155759
    Abstract: The present invention is related to novel compounds of formula (I) that inhibit the activity of the FabI enzyme which are therefore useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: December 18, 2018
    Assignee: Janssen Sciences Ireland UC
    Inventors: Jerôme Emile Georges Guillemont, David Francis Alain Lançois, Magali Madeleine Simone Motte, Anil Koul, Wendy Mia Albert Balemans, Eric Pierre Alexandre Arnoult
  • Antibacterial compounds
    Patent number: 9951032
    Abstract: The present invention relates to the following compounds for use in the treatment of a bacterial infection wherein the integers are as defined in the description. The invention also relates to compounds for use as medicaments, pharmaceutical compositions and some novel compounds.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: April 24, 2018
    Assignee: JANSSEN SCIENCES IRELAND UC
    Inventors: Jérôme Émile Georges Guillemont, Magali Madeleine Simone Motte, Anil Koul, Nacer Lounis
  • RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS
    Publication number: 20180105529
    Abstract: The invention concerns novel substituted pyrazolo- and triazolo-pyrimidine compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.
    Type: Application
    Filed: April 27, 2016
    Publication date: April 19, 2018
    Applicant: Janssen Sciences Ireland UC
    Inventors: David Francis Alain LANÇOIS, Jérôme Émile Georges GUILLEMONT, Pierre Jean-Marie Bernard RABOISSON, Dirk André Emmy ROYMANS, Boris ROGOVOY, Vadim BICHKO, Delphine Yvonne Raymonde LARDEAU, Antoine Benjamin MICHAUT, Anil KOUL